Rating Change
Morgan Stanley reiterated its Equal-Weight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on October 07, 2026.
reiterateNASDAQ:REGN
Morgan Stanley Reiterates Equal-Weight Rating on Regeneron Pharmaceuticals, Inc. (REGN)
Morgan Stanley reiterated its Equal-Weight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on October 07, 2026.
At publication ·
What changed
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) · reiterate
- Firm
- Morgan Stanley
- Rating
- Equal-Weight to Equal-Weight
- Price at event
- $742.12
- Market capitalization
- $77.2B
At a glance
Key takeaways
- Morgan Stanley maintained an Equal-Weight rating on Regeneron Pharmaceuticals (REGN) on October 7, 2026, suggesting the stock is fairly valued relative to the market.
Market Context
Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $742.12 with a market capitalization of $77.2B. The stock has declined 5.2% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Regeneron Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Regeneron Pharmaceuticals, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Oct 07, 2026 | Truist Securities | Buy | N/A |
| Oct 06, 2026 | JP Morgan | Overweight | N/A |
| Oct 01, 2026 | Argus Research | Buy | N/A |
| Oct 01, 2026 | Jefferies | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View REGN Stock Page
Frequently Asked Questions
What does the Equal-Weight rating mean for REGN?
A rating of Equal-Weight from Morgan Stanley reflects the analyst's outlook on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the REGN forecast page.
